{"public_id":"cl_5115e7d84618217ac4a17ebc5bc256a7","status":"active","superseded_by_public_id":null,"corpus_id":207577951,"text":"RECAP provided long-term follow-up safety data for pirfenidone in patients with idiopathic pulmonary fibrosis after completion of ASCEND 016 or CAPACITY 004/006 phase 3 trials.","confidence":0.97,"paper":{"corpus_id":207577951,"title":"An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP)","url":"https://sah.borca.ai/papers/207577951"},"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.97,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_66c5855c14a9e655a5ff3d273fcb9275","name":"idiopathic pulmonary fibrosis","description":"A progressive fibrosing interstitial lung disease studied as the condition treated with pirfenidone.","types":["disease","condition"],"url":"https://sah.borca.ai/concepts/co_66c5855c14a9e655a5ff3d273fcb9275"},{"public_id":"co_7409daee74d4701ab4dfd47abdcc218f","name":"pirfenidone","description":"An antifibrotic drug evaluated here for long-term safety in idiopathic pulmonary fibrosis.","types":["drug","treatment"],"url":"https://sah.borca.ai/concepts/co_7409daee74d4701ab4dfd47abdcc218f"},{"public_id":"co_bb2628c3df9c561b3f862768f2fd8216","name":"RECAP","description":"An open-label extension study that followed patients with idiopathic pulmonary fibrosis who had completed prior pirfenidone phase 3 trials.","types":["clinical study","open-label extension study"],"url":"https://sah.borca.ai/concepts/co_bb2628c3df9c561b3f862768f2fd8216"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_5115e7d84618217ac4a17ebc5bc256a7"}